An ideal clinical assay for detecting circulating tumor cells should be high throughput (as simple as a one-step reaction) and highly sensitive (requiring as little as one drop of blood). The current assay to detect circulating tumor cells is time- and labor-consuming multi-step procedure, requiring isolation of tumor cells, staining with antibodies, and repeated washes to reduce background. To overcome these obstacles, we have developed a unique aptamer probe that carries a "tumor cell-activatable" reporting system. The aptamer probes specifically bind tumor biomarker(s) and are optically silent in the absence of target cells, thus giving no to minimal background. To translate these research findings to the clinic, the goal of this study is to develop a novel technology for circulating tumor cell detectio in a "One-Drop (of blood)-One-Step Assay" (ODOSA).
The specific aims of this proposal are to: 1. Optimize sensitivity and specificity of the aptamer probes for the ODOSA technology;2. Develop a multi-sample and high-throughput platform for the ODOSA technology;and 3. Validate the ODOSA technology in clinical specimens. Scientifically, this study presents an innovative concept that tumor cells can be specifically detected by activating the aptamer probes through a natural cellular process with exclusively intracellular signals and no background. Technically, the ODOSA is a technological breakthrough over the current antibody-mediated assays. Clinically, the ODOSA provides a high- throughput and multi-sample platform, and enables physicians to detect one single circulating tumor cell among millions of cells in real time using a minimal amount of blood. There is no alternative clinical assay available to date.

Public Health Relevance

The proposed One-Drop (of blood)-One-Step Assay (ODOSA) presents transformative technological advance that would allow physicians to detect various circulating cancers in one drop of a patient's blood. The current antibody-mediated process is labor and time intensive, with multiple steps requiring large initial sample volumes. The proposed ODOSA is a technological breakthrough. Clinical implementation of the ODOSA would enable early detection and accurate monitoring of therapeutic response of cancer tumors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants Phase II (R33)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-4 (O1))
Program Officer
Sorbara, Lynn R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Methodist Hospital Research Institute
United States
Zip Code
Wen, Jianguo; Tao, Wenjing; Kuiatse, Isere et al. (2015) Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions. Int J Cancer 136:991-1002
Zhao, Nianxi; Pei, Sung-nan; Parekh, Parag et al. (2014) Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers. Int J Biochem Cell Biol 51:10-8
Zeng, Zihua; Parekh, Parag; Li, Zheng et al. (2014) Specific and sensitive tumor imaging using biostable oligonucleotide aptamer probes. Theranostics 4:945-52
Wen, Jianguo; Li, Hangwen; Tao, Wenjing et al. (2014) High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells. Br J Haematol 166:711-9
Hong, Bin; Zu, Youli (2013) Detecting circulating tumor cells: current challenges and new trends. Theranostics 3:377-94
Parekh, Parag; Kamble, Sanchit; Zhao, Nianxi et al. (2013) Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 34:8909-17
Zhao, Nianxi; You, Jian; Zeng, Zihua et al. (2013) An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small 9:3477-84
Parekh, Parag; Kamble, Sanchit; Zhao, Nianxi et al. (2013) Biostable ssDNA aptamers specific for Hodgkin lymphoma. Sensors (Basel) 13:14543-57